Trials / Completed
CompletedNCT01419327
Fosrenol Post-marketing Surveillance for Hemodialysis in Japan
Special Drug Use Investigation of Fosrenol (Long-term Investigation for Patients With Hemodialysis)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,267 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in hemodialysis who received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. A total 3,000 patients will be recruited and followed 5 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet | Patients in hemodialysis who have received Fosrenol for hyperphosphatemia. |
Timeline
- Start date
- 2009-03-23
- Primary completion
- 2019-01-30
- Completion
- 2019-05-28
- First posted
- 2011-08-18
- Last updated
- 2020-05-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01419327. Inclusion in this directory is not an endorsement.